PDT Partners LLC Has $1.99 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

PDT Partners LLC raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 48.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,008 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,898 shares during the period. PDT Partners LLC’s holdings in Supernus Pharmaceuticals were worth $1,989,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Supernus Pharmaceuticals by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock valued at $222,411,000 after buying an additional 22,852 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock valued at $54,633,000 after purchasing an additional 28,517 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after purchasing an additional 95,777 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock worth $27,242,000 after purchasing an additional 40,968 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Supernus Pharmaceuticals by 18.3% during the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company’s stock valued at $25,933,000 after purchasing an additional 110,867 shares during the period.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $32.49 on Wednesday. The company’s fifty day moving average price is $31.88 and its two-hundred day moving average price is $34.99. The firm has a market capitalization of $1.81 billion, a PE ratio of 30.36 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 17th.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.